Japan Lifeline Co., Ltd.

Tokyo Stock Exchange 7575.T

Japan Lifeline Co., Ltd. EBIT Margin for the year ending March 31, 2024: 20.63%

Japan Lifeline Co., Ltd. EBIT Margin is 20.63% for the year ending March 31, 2024, a 8.67% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Japan Lifeline Co., Ltd. EBIT Margin for the year ending March 31, 2023 was 18.99%, a -3.42% change year over year.
  • Japan Lifeline Co., Ltd. EBIT Margin for the year ending March 31, 2022 was 19.66%, a 113.33% change year over year.
  • Japan Lifeline Co., Ltd. EBIT Margin for the year ending March 31, 2021 was 9.21%, a -54.29% change year over year.
  • Japan Lifeline Co., Ltd. EBIT Margin for the year ending March 31, 2020 was 20.16%, a -15.95% change year over year.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
Loading...
Tokyo Stock Exchange: 7575.T

Japan Lifeline Co., Ltd.

CEO Mr. Keisuke Suzuki
IPO Date Jan. 4, 2000
Location Japan
Headquarters Tennoz Ocean Square
Employees 1,216
Sector Health Care
Industries
Description

Japan Lifeline Co., Ltd., a medical device company, develops, produces, imports, distributes, and trades in cardiovascular related medical devices in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, and radio-frequency transseptal needles. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts; and transvascular intervention products include PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and atrial septal defect closure devices. The company offers gastrointestinal intervention products that consist of radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.

Similar companies

7988.T

Nifco Inc.

USD 23.40

-1.72%

6849.T

Nihon Kohden Corporation

USD 12.76

-1.43%

6869.T

Sysmex Corporation

USD 18.62

0.90%

4849.T

en-japan inc.

USD 12.58

-1.13%

7747.T

Asahi Intecc Co., Ltd.

USD 15.87

-0.88%

StockViz Staff

January 15, 2025

Any question? Send us an email